A recent study published in Diabetes, Obesity and Metabolism indicates that GLP-1 drugs, commonly used to treat type 2 diabetes and obesity, may also lower the risk of age-related macular degeneration (AMD). The research analyzed data from over 157,000 patients and found an 18%…
As the use of GLP-1 medications rises significantly in the U.S., concerns have emerged regarding President Trump's derogatory references to these drugs as 'fat shots.' Medical pro…
Researchers at Stanford Medicine have discovered a naturally occurring peptide, BRP, that may suppress appetite through a targeted pathway, potentially offering a new approach to…
The FDA is reviewing seven unapproved peptides that have gained popularity for their purported health benefits, including weight loss and chronic disease management. The review co…
Research from the University of Granada indicates that a 12-week intermittent fasting program can help individuals maintain weight loss for at least a year after the intervention.…
As GLP-1 medications like Wegovy and Mounjaro gain popularity for weight loss, concerns arise about the potential for yo-yo dieting once treatment stops. Evidence suggests that ma…
A recent analysis reveals that while obesity drugs like GLP-1s can lead to significant weight loss, they often do not enhance quality of life or cardiovascular health for many pat…
Recent discussions highlight the potential for yo-yo dieting associated with GLP-1 weight-loss medications like Wegovy and Mounjaro. While these drugs can be effective in aiding w…
A recent study examined how socioeconomic status (SES) affects the response to pediatric obesity treatment in Germany and Sweden. Analyzing data from over 45,000 children, the res…